Evidence map›Paper›PMID 37217965›Full record

ArticleTrials2023

Optimization of smartphone psychotherapy for depression and anxiety among patients with cancer using the multiphase optimization strategy (MOST) framework and decentralized clinical trial system (SMartphone Intervention to LEssen depression/Anxiety and GAIN resilience: SMILE AGAIN project): a protocol for a randomized controlled trial.

Megumi Uchida, Toshiaki A Furukawa, Takuhiro Yamaguchi, Fuminobu Imai, Kanae Momino, Fujika Katsuki, Naomi Sakurai, Tempei Miyaji, Masaru Horikoshi, Hiroji Iwata and 10 more

Abstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Megumi UchidaDepartment of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Toshiaki A FurukawaDepartment of Health Promotion and Human Behavior, Graduate School of Medicine/School of Public Health, Kyoto University, Kyoto, Japan.
Takuhiro YamaguchiDivision of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan.
Fuminobu ImaiDepartment of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Kanae MominoDepartment of Nursing Administration and Management, Nagoya City University Graduate School of Nursing, Nagoya, Japan.
Fujika KatsukiDepartment of Psychiatric and Mental Health Nursing, Nagoya City University Graduate School of Nursing, Nagoya, Japan.
Naomi SakuraiCancer Solutions, Tokyo, Japan.
Tempei MiyajiDepartment of Clinical Trial Data Management, Tokyo University Graduate School of Medicine, Tokyo, Japan.
Masaru HorikoshiNational Center for Cognitive Behavior Therapy and Research, National Center of Neurology and Psychiatry, Tokyo, Japan.
Hiroji IwataDepartment of Breast Oncology, Aichi Cancer Center, Nagoya, Japan.
Sadamoto ZendaDivision of Radiation Oncology, National Cancer Center Hospital East, Chiba, Japan.
Tsuguo IwataniDepartment of Breast Surgery, National Cancer Center Hospital East, Chiba, Japan.
Asao OgawaDepartment of Psycho-Oncology Service, National Cancer Center Hospital East, Kashiwa, Japan.
Akira InoueDepartment of Palliative Medicine, Tohoku University School of Medicine, Miyagi, Japan.
Masakazu AbeDivision of Gynecologic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Tatsuya ToyamaDepartment of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.
Yosuke UchitomiBehavioral and Survivorship Research Group, Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital, Tokyo, Japan.
Hiromichi MatsuokaDepartment of Psycho-Oncology, National Cancer Center Hospital, Tokyo, Japan.
Hisashi NomaInstitute of Statistical Mathematics, Tokyo, Japan.
Tatsuo AkechiDepartment of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan. takechi@med.nagoya-cu.ac.jp.ORCID http://orcid.org/0000-0003-1100-7518

Funding

the Japan Agency for Medical Research and Development 20ck0106600h0001the Japanese Ministry of Education, Culture, Science and Technology 19H03586
6 · The paper itself

Abstract

backgroundCancer patients experience various forms of psychological distress. Their distress, mainly in the form of depression and anxiety, leads to poor quality of life, increased medical spending due to frequent visits, and decrease in treatment adherence. It is estimated that 30-50% among them would require support from mental health professionals: in reality, much less actually receive such support partly due to a shortage of qualified professionals and also due to psychological barriers in seeking such help. The purpose of the present study is to develop the easily accessible and the most efficient and effective smartphone psychotherapy package to alleviate depression and anxiety in cancer patients.

methodsBased on the multiphase optimization strategy (MOST) framework, the SMartphone Intervention to LEssen depression/Anxiety and GAIN resilience project (SMILE-AGAIN project) is a parallel-group, multicenter, open, stratified block randomized, fully factorial trial with four experimental components: psychosocial education (PE), behavioral activation (BA), assertion training (AT), and problem-solving therapy (PS). The allocation sequences are maintained centrally. All participants receive PE and then are randomized to the presence/absence of the remaining three components. The primary outcome of this study is the Patient Health Questionnaire-9 (PHQ-9) total score, which will be administered as an electronic patient-reported outcome on the patients' smartphones after 8 weeks. The protocol was approved by the Institutional Review Board of Nagoya City University on July 15, 2020 (ID: 46-20-0005). The randomized trial, which commenced in March 2021, is currently enrolling participants. The estimated end date for this study is March 2023. DISCUSSION: The highly efficient experimental design will allow for the identification of the most effective components and the most efficient combinations among the four components of the smartphone psychotherapy package for cancer patients. Given that many cancer patients face significant psychological hurdles in seeing mental health professionals, easily accessible therapeutic interventions without hospital visits may offer benefits. If an effective combination of psychotherapy is determined in this study, it can be provided using smartphones to patients who cannot easily access hospitals or clinics.

trial registrationUMIN000041536, CTR. Registered on 1 November 2020  https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000047301 .

Indexed as

NeoplasmsSmartphoneAnxietyDepressionHumansMulticenter Studies as TopicPsychotherapyQuality of LifeRandomized Controlled Trials as TopicTreatment OutcomeAnxietyAssertion trainingBehavioral activationCancerDepressionProblem-solving therapyPsychoeducationSmartphone psychotherapy

Identifiers

PMID37217965
PMCPMC10201730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.